Cerebral glucose metabolism in preclinical and prodromal Alzheimers disease

Expert Review of Neurotherapeutics

Volumn 10, Issue 11, 2010, Pages 1667-1673

  Herholz, Karl ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Alzheimers disease; clinical trial; early diagnosis; F 2 fluoro 2 deoxy D glucose; mild cognitive impairment biomarkers; positron emission tomography

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ALZHEIMER DISEASE; BRAIN FUNCTION; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; DRUG UPTAKE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; LONGITUDINAL STUDY; METABOLIC DISORDER; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; RELIABILITY; REVIEW; RISK ASSESSMENT;

ALZHEIMER DISEASE; BRAIN; COGNITION DISORDERS; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 78049477643     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.136     Document Type: Review

References (73)

1. Dubois B, Feldman HH, Jacova C et al Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734-746 (2007).
2. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch. Neurol. 62, 1160-1163; discussion 1167 (2005).
3. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC. Apolipoprotein E z4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the cache county study. Arch. Gen. Psychiatry 61, 518-524 (2004).
4. Herholz K. FDG-PET: Imaging cerebral glucose metabolism with positron emission tomography. In: The Dementias-Early Diagnosis and Evaluation. Herholz K, Perani D, Morris C (Eds). Taylor & Francis, NY, USA, 229-252 (2006).
5. Langbaum JB, Chen K, Lee W et al Categorical and correlational analyses of baseline fuorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). NeuroImage 45, 1107-1116 (2009).
6. Fleisher AS, Donohue M, Chen K, Brewer JB, Aisen PS. Applications of neuroimaging to disease-modifcation trials in Alzheimer's disease. Behav. Neurol. 21, 129-136 (2009).
7. 18F]FDG, version 2. Eur. J. Nucl. Med. Mol. Imaging DOI: 10.1007/s00259-009-1264-0 (2009) (Epub ahead of print).
8. Herholz K. PET studies in dementia. Ann. Nucl. Med. 17, 79-89 (2003).
9. Herholz K, Perani D, Salmon E et al. Comparability of FDG-PET studies in probable Alzheimer's disease. J. Nucl. Med. 34, 1460-1466 (1993).
10. Herholz K, Nordberg A, Salmon E et al Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 10, 494-504 (1999).
11. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fuorine-18-FDG-PET J. Nucl. Med. 36, 1238-1248 (1995).
12. 18F] FDG-PET: a clinical validation of statistical parametric mapping. Neuroimage 9, 63-80 (1999).
13. Herholz K, Salmon E, Perani D et al Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG-PET. Neuroimage 17, 302-316 (2002).
14. Kippenhan JS, Barker WW, Nagel J, Grady C, Duara R. Neural-network classifcation of normal and Alzheimer's disease subjects using high-resolution and low-resolution PET cameras. J. Nucl. Med. 35, 7-15 (1994).
15. Sayeed A, Petrou M, Spyrou N, Kadyrov A, Spinks T Diagnostic features of Alzheimer's disease extracted from PET sinograms. Phys. Med. Biol. 47, 137-148 (2002).
16. Nobili F, Salmaso D, Morbelli S et al Principal component analysis of FDG-PET in amnestic MCI. Eur. J. Nucl. Med. Mol Imaging 35, 2191-2202 (2008).
17. Salmon E, Kerrouche N, Perani D et al On the multivariate nature of brain metabolic impairment in Alzheimer's disease. Neurobiol. Aging 30, 186-197 (2009).
18. Higdon R, Foster NL, Koeppe RA et al A comparison of classifcation methods for differentiating frontotemporal dementia from Alzheimer's disease using FDG-PET imaging. Stat. Med. 23, 315-326 (2004).
19. 18F]2-fuoro-2-deoxy-D-glucose: a critical appraisal of optimization procedures. J. Cereb. Blood Flow Metab. 5, 115-125 (1985).
20. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum. Brain Mapp. 2, 189-210 (1995).
21. Yakushev I, Hammers A, Fellgiebel A et al. SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging. Neuroimage 44, 43-50 (2009).
22. Heiss WD, Pawlik G, Holthoff V, Kessler J, Szelies B. PET correlates of normal and impaired memory functions. Cerebrovasc. Brain Metab. Rev. 4, 1-27 (1992).
23. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann. Neurol. 54, 343-351 (2003).
24. De Santi S, de Leon MJ, Rusinek H et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol. Aging 22, 529-539 (2001).
25. 18F-FDG-PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J. Nucl. Med. 49, 390-398 (2008).
26. Aston JA, Cunningham VJ, Asselin MC, Hammers A, Evans AC, Gunn RN. Positron emission tomography partial volume correction: estimation and algorithms. J. Cereb. Blood Flow Metab. 22, 1019-1034 (2002).
27. 18F-FDG-PET. J. Nucl. Med. 49, 44-49 (2008).
28. Mourik JE, Lubberink M, van Velden FH et al. In vivo validation of reconstruction-based resolution recovery for human brain studies. J. Cereb. Blood Flow Metab. 30(2), 381-389 (2009).
29. Pardo JV, Lee JT, Sheikh SA et al. Where the brain grows old: decline in anterior cingulate and medial prefrontal function with normal aging. Neuroimage 35, 1231-1237 (2007).
30. Sakamoto S, Ishii K, Sasaki M et al. Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. J. Neurol. Sci. 200, 27-32 (2002).
31. Haense C, Herholz K, Jagust WJ, Heiss WD. Performance of FDG-PET for detection of alzheimer's disease in two independent multicenter samples (NEST-DD and ADNI). Dement. Geriatr. Cogn. Disord. 28, 259-266 (2009).
32. Silverman DH, Small GW, Chang CY et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286, 2120-2127 (2001).
33. Foster NL, Heidebrink JL, Clark CM et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 130, 2616-2635 (2007).
34. Jagust W, Reed B, Mungas D, Ellis W, DeCarli C. What does fuorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69, 871-877 (2007).
35. Small GW, Mazziotta JC, Collins MT et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273, 942-947 (1995).
36. Reiman EM, Caselli RJ, Yun LS et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the £ 4 allele for apolipoprotein E. N Eng J. Med. 334, 752-758 (1996).
37. Reiman EM, Chen K, Alexander GE et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl Acad. Sci. USA 101, 284-289 (2004).
38. Small GW, Ercoli LM, Silverman DH et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl Acad. Sci. USA 97, 6037-6042 (2000).
39. de Leon MJ, Convit A, Wolf OT et al. Prediction of cognitive decline in normal elderly subjects with 2-F-18-fuoro-2-deoxy-D-glucose positron-emission tomography (FDG-PET). Proc. Natl Acad. Sci. USA 98, 10966-10971 (2001).
40. Hampel H, Frank R, Broich K et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 9, 560-574 (2010).
41. Mosconi L, Tsui WH, DeSanti S et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 64 1860-1867 (2005).
42. Clerici F, Del Sole A, Chiti A et al. Differences in hippocampal metabolism between amnestic and non-amnestic MCI subjects: automated FDG-PET image analysis. Q. J. Nucl. Med. Mol. Imaging 53, 646-657 (2009).
43. Jauhiainen AM, Kangasmaa T, Rusanen M et al. Differential hypometabolism patterns according to mild cognitive impairment subtypes. Dement. Geriatr. Cogn. Disord. 26, 490-498 (2008).
44. Chetelat G, Desgranges B, Landeau B et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 131, 60-71 (2008).
45. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 42, 85-94 (1997).
46. Berent S, Giordani B, Foster N et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. J. Psychiatr. Res. 33, 7-16 (1999).
47. Arnaiz E, Jelic V, Almkvist O et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 12, 851-855 (2001).
48. 18) F-FDG-PET. J. Nucl. Med. 46, 1625-1632 (2005).
49. Anchisi D, Borroni B, Franceschi M et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch. Neurol. 62, 1728-1733 (2005).
50. 18F-fuoro-2-deoxy-D-glucose positron emission tomography fndings in patients with mild cognitive impairment. Biol. Psychiatry 56, 279-283 (2004).
51. Fellgiebel A, Scheurich A, Bartenstein P, Muller MJ. FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Res. 155, 167-171 (2007).
52. Landau SM, Harvey D, Madison CM et al.; on behalf of the Alzheimer's Disease Neuroimaging Initiative. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75, 230-238 (2010).
53. 18F-FDG-PET Database of longitudinally confrmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease. J. Nucl. Med. 48, 1129-1134 (2007).
54. Drzezga A, Lautenschlager N, Siebner H et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging 30, 1104-1113 (2003).
55. Jagust WJ, Friedland RP, Budinger TF, Koss E, Ober B. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology 38, 909-912 (1988).
56. Haxby JV, Grady CL, Koss E et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch. Neurol. 47, 753-760 (1990).
57. Brown DRP, Hunter R, Wyper DJ et al. Longitudinal changes in cognitive function and regional cerebral function in Alzheimer's disease: A SPECT blood fow study. J. Psychiatr. Res. 30, 109-126 (1996).
58. Mosconi L, Mistur R, Switalski R et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verifed Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 36, 811-822 (2009).
59. Mosconi L, Perani D, Sorbi S et al. Brain metabolism predicts conversion from mild cognitive impairment to dementia in individual carriers of the ApoE E4 allele. Eur. J. Neurol. 11(Suppl. 2), 27 (2004).
60. Haxby JV, Rapoport SI. Abnormalities of regional brain metabolism in Alzheimer's disease and their relation to functional impairment. Prog. Neuropsychopharmacol. Biol. Psychiatry 10, 427-438 (1986).
61. Desgranges B, Baron JC, Lalevee C et al. The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET: relationship to degree of deterioration. Brain 125, 1116-1124 (2002).
62. Cummings JL. Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiol. Aging 31, 1481-1492 (2010).
63. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry 159, 738-745 (2002).
64. Hirono N, Hashimoto M, Ishii K, Kazui H, Mori E. One-year change in cerebral glucose metabolism in patients with Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 16, 488-492 (2004).
65. Holland D, Brewer JB, Hagler DJ et al. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc. Natl Acad. Sci. USA 106, 20954-20959 (2009).
66. Landau SM, Harvey D, Madison CM et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging DOI: 10.1016/j. neurobiolaging.2009.07.002 (2009).
67. Chen K, Langbaum JB, Fleisher AS et al. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defned statistical region-of-interest: fndings from the Alzheimer's Disease Neuroimaging Initiative. Neuroimage 51, 654-664 (2010).
68. Garibotto V, Borroni B, Kalbe E et al. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology 71, 1342-1349 (2008).
69. 18F] FDG-PET study. Neurology 68, 501-508 (2007).
70. Li Y, Rinne JO, Mosconi L et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 35, 2169-2181 (2008).
71. Cohen AD, Price JC, Weissfeld LA et al. Basal cerebral metabolism may modulate the cognitive effects of Ap in mild cognitive impairment: an example of brain reserve. J. Neurosci. 29, 14770-14778 (2009).
72. 18F-FDG and PiB PET in cognitive impairment. J. Nucl. Med. 50, 878-886 (2009).
73. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 60, 1374-1377 (2003).